Neurogene (NGNE) Profit After Tax (2013 - 2026)
Neurogene (NGNE) reported Profit After Tax of -$30.9 million for Q1 2026, down 36.73% on a YoY basis from -$48.8 million in Q1 2025, and down 24.68% quarter-over-quarter from -$24.8 million in Q4 2025.
Neurogene (NGNE) Profit After Tax (2013 - 2026) Analysis & Trends
Neurogene has reported Profit After Tax for 14 years, with the latest figure at -$30.9 million in Q1 2026.
- For the quarter ending Q1 2026, Profit After Tax fell 36.73% year-over-year to -$30.9 million; the trailing twelve-month figure through Mar 2026 stood at -$98.7 million (down 22.13% YoY), and the FY2025 full-year result was -$90.4 million, down 20.37% from the prior year.
- Profit After Tax for Q1 2026 stood at -$30.9 million, down from -$24.8 million in the prior quarter.
- The five-year high for Profit After Tax was $13.7 million in Q4 2023, with the low at -$30.9 million in Q1 2026.
- Historically, Profit After Tax has averaged -$16.3 million across 5 years, with a median of -$16.9 million in 2024.
- Annual changes were most pronounced in 2023 — Profit After Tax surged 216.99% — and 2024, when it plunged 242.6%.
- Neurogene's Profit After Tax stood at -$11.7 million in 2022, then surged by 216.99% to $13.7 million in 2023, then sank by 242.6% to -$19.5 million in 2024, then slipped by 27.29% to -$24.8 million in 2025, then fell by 24.68% to -$30.9 million in 2026.
- The last three Profit After Tax figures came in at -$30.9 million (Q1 2026), -$24.8 million (Q4 2025), and -$21.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.90 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.63 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -753,254.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.74 Mn |
| 10 | Neurogene | 216.17 Mn | 216.17 Mn | - | -30.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -30.90 Mn |
| Dec 31, 2025 | -24.78 Mn |
| Sep 30, 2025 | -20.95 Mn |
| Jun 30, 2025 | -22.02 Mn |
| Mar 31, 2025 | -22.60 Mn |
| Dec 31, 2024 | -19.47 Mn |
| Sep 30, 2024 | -20.22 Mn |
| Jun 30, 2024 | -18.49 Mn |
| Mar 31, 2024 | -16.92 Mn |
| Dec 31, 2023 | 13.65 Mn |
| Sep 30, 2023 | -14.58 Mn |
| Jun 30, 2023 | -11.86 Mn |
| Mar 31, 2023 | -12.26 Mn |
| Dec 31, 2022 | -11.67 Mn |
| Sep 30, 2022 | -13.07 Mn |
| Jun 30, 2022 | -15.69 Mn |
| Mar 31, 2022 | -15.35 Mn |
| Dec 31, 2021 | -15.17 Mn |
| Sep 30, 2021 | -15.45 Mn |
| Jun 30, 2021 | -15.13 Mn |